Platelet Rich Plasma in the Prevention of Adhesion Reformation
Launched by FU XING HOSPITAL, CAPITAL MEDICAL UNIVERSITY · Sep 19, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Asherman syndrome, which occurs after trauma to the basalis layer of the endometrium. It seems that the role of postoperative platelet rich plasma（PRP）therapy in the prevention of recurrence of IUA is still controversial. To investigate if PRP therapy can prevent adhesion reformation after adhesiolysis.
After the completion of hysteroscopic adhesiolysis, recruited patients will be randomized to one of the two treatment groups by computer-generated numbers: having PRP after hysteroscopic adhesiolysis; and the control group without PRP treatment. A second-look hysteroscopy and ultrasound ass...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of Asherman's syndrome. AFS score \>7.
- Exclusion Criteria:
- • 1. Leiomyoma;
- • 2. Endometrial polyps;
- • 3. Ppolycystic ovarian syndrome (PCOS).
About Fu Xing Hospital, Capital Medical University
Fu Xing Hospital, affiliated with Capital Medical University, is a leading medical institution dedicated to advancing healthcare through rigorous clinical research and innovative patient care. Renowned for its commitment to medical excellence, the hospital fosters a collaborative environment that integrates clinical practice, education, and research. With a focus on ethical standards and patient safety, Fu Xing Hospital actively engages in a diverse range of clinical trials aimed at improving treatment outcomes and enhancing the understanding of various medical conditions. The institution's strong academic foundation and experienced research team contribute to its reputation as a trusted sponsor in the clinical trial landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported